



This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|-----------------|---|--|--|---|
| Hepatic disease | | | | |
| Liver disease | Serpin peptidase inhibitor, clade A (SERPINA I) | Studies in patients suggest an allele of the <i>SERPINA1</i> gene could help identify cystic fibrosis (CF) patients at risk of developing CF-associated liver disease. Genetic polymorphism studies identified a Z allele variant (G4627A) in <i>SERPINA1</i> that was significantly associated with CF-associated liver disease (<i>p</i> =1.5×10 ⁻⁸). Next steps include studying the functional relevance of the <i>SERPINA1</i> risk allele in CF patients. | Work unpatented; licensing status not applicable | Bartlett, J.R. et al. JAMA; published online Sept. 8, 2009; doi:10.1001/jama.2009.1295 Contact: Michael R. Knowles, The University of North Carolina at Chapel Hill, Chapel Hill, N.C. e-mail: knowles@med.unc.edu |
| | | SciBX 2(38); doi:10.1038/scibx.2009.1441 Published online Oct. 1, 2009 | | |